DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer Visit Post
2 BlueRock secures FDA fast track; Omniscient rakes in $29M; Neuspera’s nerve implant gets a $65M boost Rivus’ therapy nabs $35M Visit Post
3 Arrowhead's ARO-ENaC Clinical Trial; Sartorius Acquires Stake in CellGenix; AGC Biologics's Cell & Gene Therapy; Sirnaomics Secures $105 Million Visit Post
4 Intellia's Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly's Diabetes Blockbuster Tirzepatide; Polyphor’s Bleak Future Visit Post
5 Insilico Medicine raises $255M; Sanofi & Translate Bio initiate trial; Medtronic gains expanded FDA approval; Blackstone, Cellex & Intellia form CAR-T startup Visit Post
6 Horizon/ Arrowhead Deal; Dr Reddy's Lab’s Drug US Launch; Targovax’s ONCOS-102; RedHill's Oral Opaganib in COVID-19 Visit Post
7 Mallinckrodt earns FDA nod for skin therapy; RayzeBio secures $108M; VectorY raises $38M; Umoja banks $210M Visit Post
8 Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies; Progentec and GSK collaborate; Kozin bags $60M Visit Post
9 Biogen’s Alzheimer’s Drug; FDA approval to Novo Nordisk’s Wegovy; Bluebird's Gene Therapy Visit Post
10 Pieris-Genentech deal; Xilio inks deal with Merck; BMS taps Xencor's tech; GenSight's gene therapy reports partial recovery Visit Post
11 Ocugen-Bharat Biotech’s Covaxin Against B.1.617 Corona Variant; uniQure Shares; J&J Covid Vaccine; Sanofi-Moderna COVID Vaccine Deal Visit Post
12 Vertex leads in CRISPR Therapeutics deal; Update for Phase 2 clinical trial of KVD824; Ovid dumps lead program; Virta Health pulls in $133M Visit Post
13 Lilly’s Retevmo shows promise; CeQur tanks up on $110M in funding; Repertoire secures $189M; Recursion sets terms for $306M IPO Visit Post
14 Biohaven's Troriluzole Failure; Daiichi/ AZ's Enhertu; Fujifilm & Manufacturing Spree; J&J's Darzalex Faspro Visit Post
15 Fosun-BioNTech's COVID-19 vaccine; Multiple Sclerosis research update; Vosoritide nabs FDA review; FDA nods to paclitaxel-coated Ranger balloon for PAD Visit Post
16 Novartis taps Molecular Partners to combat COVID-19; GSK culls phase 2 asthma drug; Exact Sciences acquires Thrive for $ 2.15 B; EQRx-CStone's deal for checkpoint inhibitors Visit Post
17 Bayer eyes AskBio’s Gene Therapies; Novartis' Iptacopan; Forma's IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic Visit Post
18 GSK's RSV vaccine; SparingVision's interest in gene therapy; InCarda's raise; BridgeBio's R&D deal Visit Post
19 Amylyx's neuron-protecting drug slows ALS decline; Antisense drugs could help fight ALS and dementia; CAR-T research updates; Orca and Lyell announces research partnership Visit Post
20 FDA rejects BioMarin's Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes Visit Post
21 Startup focuses tumors with CAR-T; AbCellera grabs USD 105M; Gilead inks USD 2B deal; GSK’s anti-BCMA antibody receives a boost Visit Post
22 CanSino deals with Precision; Atea raises USD 215 M; Applied Molecular Transport targets for USD 100 M IPO; Cell therapy repairs multiple sclerosis in mice Visit Post
23 CAR-T cell therapy market for Non-Hodgkin lymphoma: Future prospects, and untapped opportunities Visit Post
24 Future Perspectives Of CAR-T Cell Therapy Market In Acute Lymphoblastic Leukemia (ALL) Visit Post
25 CAR-T in killing tumors; Amunix raises $73M; Autism findings in protein-targeted treatment Visit Post
26 Gene therapy might make cocaine less addictive Visit Post
27 Why should every company working on CAR-T therapy attend CAR TCR Summit Europe? Visit Post
28 In a blind race to cure HIV, can Gene therapy be a deal-breaker? Visit Post
29 Autologous cell therapy market: A new paradigm for kidney diseases Visit Post
30 Japan is transforming its Healthcare sector through Regenerative Medicine Visit Post
31 Zogenix acquires Modis Therapeutics; Amgen buys Otezla; CRISPR slows down the Breast cancer rate Visit Post
32 Notizia Visit Post
33 Notizia Visit Post
34 Notizia Visit Post
35 Can commoners afford to spend million dollars on GENE Therapy? Visit Post
36 Gene Therapy in Oncology: Innovation to Commercialization Visit Post
37 Inozyme Raises $67M; Shanghai Miracogen partners with Synaffix; EdiGENE raises $15M; Antengene announces its expansion Visit Post
38 The promising Pipeline for Gene Therapy In Oncology Visit Post
39 Notizia Visit Post
40 The Business Cocktail Visit Post
41 BioNTech lines up $800M; Deerfield remunerates; Britain's Smith & Nephew to acquire Osiris Visit Post
42 The Business Cocktail Visit Post
43 Notizia Visit Post
44 A CRISPR WAY TO USE STEM CELLS Visit Post
45 CRISPR proves to be a blessing for LASSA fever Visit Post
46 Notizia Visit Post
47 Human cells reprogrammed to create insulin in diabetic mice Visit Post
48 Neurogene raises $68.5M; AbbVie and Teneobio sign deal; 5AM Ventures nets Visit Post
49 Genentech remunerates Xencor; XPrize upraises fund; GSK gambles Visit Post
50 Notizia Visit Post
51 Molecular Profiling Could Help in Early Lung Cancer Detection: Study Visit Post
52 Highly mutated cancers respond better to immune therapy Visit Post
53 Notizia Visit Post
54 Where in the world could the first CRISPR baby be born? Visit Post
55 Vedanta raises; Relay Therapeutics reels in; Gene therapy for SMA Visit Post
56 66 Year Ohio Woman Becomes Cancer Free, Thanks to CAR T Cell Therapy Visit Post
57 Baby gene edits could affect a range of traits Visit Post
58 Cancer Cells Trick Body’s Immunity to Survive against Treatment Visit Post
59 Researchers say CRISPR edits to a human embryo worked Visit Post
60 Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates; Celgene’s deal Visit Post
61 Gilead remunerates; Roche taps Halozyme’s drug delivery tech; Orchard Therapeutics prices its IPO Visit Post
62 Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates for RSV drug Visit Post
63 Is Gene Therapy the Next Cancer Treatment Revolution?  Visit Post
64 Hologic complements Focal; Allogene for IPO; Gamida, Novartis-backed cell therapy startup; Aduro loses partner Visit Post
65 Epic Sciences garners; Tvardi gets financing; Galera raises; Fund for cancer research Visit Post
66 Pancreatic Cancer Treatment to Stride Beyond Chemotherapy Visit Post
67 4D Molecular Therapeutics raises; Arvinas slates for IPO; Sutro ruminates for $ 75M; Emergent BioSolutions remunerates Narcan maker Visit Post
68 Snippet Visit Post
69 The Business Cocktail(Therapeutics) Visit Post
70 Personalized Medicine Approach: An Upholding Paradigm for a Promising and futuristic Patient Centric Health Care Visit Post
71 Sarepta’s deal; Fund raisings for Apexigen; Novo funded rare disease startup Visit Post
72 Snippet : Genetic Mutation Visit Post
73 Idera's drug; CRISPR increase risk; Juvenescence grabbed USD 50M; AstraZeneca, Lilly terminates Visit Post
74 Axovant rely on gene therapy; CAR-T treatments; Pfizer’s dacomitinib; Adaptimmune construct manifestation Visit Post
75 Hematopoietic Stem Cell Transplantation Visit Post
76 Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set to refile ozanimod Visit Post
77 Horizon Discovery declines Abcam’s USD 367 million takeover bid Visit Post
78 Phase 1 data of CYC065; Lysogene delays phase 3 study; Genetic disorders Diagnosis; PD-1 resistance in melanoma patients Visit Post
79 Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs Visit Post
80 Notizia Visit Post
81 Business Cocktail Visit Post
82 Business Cocktail Visit Post
83 Pandion bags $58M; Carmot Therapeutics grabs $15M; Innovent looks for IPO; Collaboration of Sandoz & Biocon Visit Post
84 Snippet Visit Post
85 Notizia Visit Post
86 NOTIZIA Visit Post
87 Novartis ventures; Bill Gates invests; Arcus Biosciences gains; Denali and Odonate seek funding; Fosun Pharma acquires Visit Post
88 Natural Killer Cell Therapies– Advancing technology increasing competition among the companies Visit Post
89 South Korean researchers influencing lift of human-embryo restrictions Visit Post
90 CAR-T Phase I trials; ContraVir Announces; Merck acquired; Excision BioTherapeutics bags $10M Visit Post
91 Social Behavior Loss Observed in Gene-edited ants through CRISPR Visit Post
92 Natural Killer Cell Therapies– Advancing technology increasing competition among the companies Visit Post
93 Bristol-Myers Squibb to nix; Pfizer commits $100M; Merck and GSK production issues; Shire unloads plant Visit Post
94 Geneticists enlist engineered virus & CRISPR to battle citrus disease Visit Post
95 Cord Blood makes brains of elderly mice young again Visit Post
96 Novartis gets CAR-T drug; Shire aims to block; Xeljanz stands; Payer snubs; Lawmakers pass a bill Visit Post
97 CRISPR finds faults in previous researches Visit Post
98 Medical tourism in India Visit Post
99 Sanofi sues Novo; Allergan gets help; Actelion snubs; Impax CEO Wilkinson out Visit Post
100 Science Events of the Year Visit Post
101 Mexico's Human-Embryo Research on Tenterhooks Visit Post
102 NgAgo gene-editing, claiming to be a better alternative to CRISPR gene editing, falls into a controversy in peer-reviewed papers Visit Post
103 CRISPR gene-editing tested in a person for the first time Visit Post
104 Antibody-Drug Conjugate and Big Pharmaceutical Companies Visit Post
105 What are your views on Gene Therapy? Visit Post
106 Antibody-Drug Conjugate Market Outlook, 2015 Report in Market Now! Visit Post
107 Next Generation Antibody-Drug Conjugate Therapeutics and Market Analysis Visit Post
108 Antibody-Drug Conjugates Market Outlook, 2015 Report Visit Post
109 Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy Visit Post
110 Gene Therapy to “Assassinate” HIV virus Visit Post
111 Suicide Gene Therapy: Where do we stand? Visit Post
112 DelveInsight’s Gene Therapy Reports: Launched Visit Post
113 A CRISPR-Cas9 approach for Gene Therapy: The Hot New R&D Field! Visit Post
114 Gene Therapy’s Emergence: The “New” approach for Huntington’s disease Visit Post
115 Are you ready to embrace Gene Therapy? Visit Post
116 DelveInsight’s Ophthalmologic disorders based Gene Therapy Reports Visit Post
117 DelveInsight’s Hematological disorders based Gene Therapy Reports Visit Post
118 DelveInsight’s Respiratory disorders based Gene Therapy Reports Visit Post
119 DelveInsight’s Immunology based Gene Therapy Reports Visit Post
120 DelveInsight’s Cardiovascular disorders based Gene Therapy Reports Visit Post
121 DelveInsight’s Musculoskeletal disorders based Gene Therapy Reports Visit Post
122 DelveInsight’s Metabolic disorders based Gene Therapy Reports Visit Post
123 DelveInsight’s Infectious disorders based Gene Therapy Reports Visit Post
124 DelveInsight’s Gastrointestinal based Gene Therapy Reports Visit Post
125 DelveInsight’s Genetic disorders based Gene Therapy Reports Visit Post
126 DelveInsight’s Dermatology based Gene Therapy Reports Visit Post
127 DelveInsight’s Genitourinary Sex hormones based Gene Therapy Reports Visit Post
128 DelveInsight’s Central Nervous System Disorders based Gene Therapy Reports Visit Post
129 DelveInsight’s Otolaryngology based Gene Therapy Reports Visit Post
130 DelveInsight’s Oncology based Gene Therapy Reports Visit Post
131 Break the Gene Therapy Barrier with DelveInsight’s Gene Therapy Reports Visit Post
132 Gene Therapy Market Visit Post